Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
uses:
None (89) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-000008A1-QINU`"', '"`UNIQ--vote-000008A2-QINU`"' (1)
starting dose:
None (89) ·
100 mg PO BID × 5 days (Macrobid) for cystitis; 50-100 mg HS for chronic prophylaxis (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (88) ·
'''Avoid at term (38-42 weeks) and during labor''' (risk of neonatal hemolytic anemia, especially with G6PD deficiency); generally safe in earlier pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid; may cause fetal harm (1) ·
Not established (1)
Showing below up to 91 results in range #1 to #91.